# Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy

Study · id `cardio:ct-nct05526703` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05526703](<https://clinicaltrials.gov/study/NCT05526703>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05526703

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 108 participants.

## Technical summary

Registry record NCT05526703. Randomized; double masking; primary purpose treatment. Start 2022-09-28 (actual); primary completion 2023-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 108 participants (planned count; ClinicalTrials.gov record NCT05526703, source copy `cardio:ctgov-nct05526703-2022-11-28`, retrieved 2026-10-26)
- Started: 2022-09-28 (actual) (ClinicalTrials.gov record NCT05526703, source copy `cardio:ctgov-nct05526703-2022-11-28`, retrieved 2026-10-26)
- Primary completion: 2023-10 (anticipated) (ClinicalTrials.gov record NCT05526703, source copy `cardio:ctgov-nct05526703-2022-11-28`, retrieved 2026-10-26)
- Completion: 2023-10 (anticipated) (ClinicalTrials.gov record NCT05526703, source copy `cardio:ctgov-nct05526703-2022-11-28`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05526703, source copy `cardio:ctgov-nct05526703-2022-11-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05526703-2022-11-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
- Condition: Essential Hypertension
- Intervention (Drug): D064, D701, placebo of D012
- Intervention (Drug): D012, placebo of D064, placebo of D701
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: 287d26c0827a53eaa2d0ddf861178a478681c8308856f2baa6073c58faa54869
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
